tofogliflozin hydrate

Small moleculeexperimental

Clinical trial activity

11 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
3

Earliest trial started May 1, 2008 (NCT00682097)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1
Mol. weight
386.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3h),2'-(2h)pyran)-3',4',5'-triol
  • apleway
  • apleway
  • csg452
  • csg452
  • csg452
  • csg452
  • deberza
  • deberza
  • ro4998452
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin
  • tofogliflozin anhydrous
  • tofogliflozin anhydrous
  • tofogliflozin hydrate
  • tofogliflozin hydrate
  • tofogliflozin hydrate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05722262Phase 1Feb 24, 2023Kowa
NCT05327127Phase 2Nov 14, 2022Kowa
NCT05469659Phase 2Sep 22, 2021Kowa, Shinshu University
NCT04237597Phase 1Dec 17, 2019Kowa
NCT02649465Phase 4Jan 1, 2016Kanazawa University, Kowa
NCT02537834Phase 4Aug 1, 2015Kowa, Sanofi
NCT02201004Phase 4Jun 1, 2014Kowa, Sanofi
NCT01044017Phase 1Dec 1, 2009Roche
NCT00933972Phase 1Jun 1, 2009Roche
NCT00800176Phase 2Jan 1, 2009Roche
NCT00682097Phase 1May 1, 2008Roche
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
KowaFor profit7432014
RocheFor profit4422008
SanofiFor profit2112014
Kanazawa UniversityAcademic/Hospital1112016
Shinshu UniversityAcademic/Hospital1112021
5 organizations
Page 1 / 1